title: Human umbilical cord blood cell therapy blocks the morphological change and recruitment of CD11b-expressing, isolectin-binding proinflammatory cells after middle cerebral artery occlusion.
abstract: Secondary neurodegeneration resulting from stroke is mediated by delayed proinflammatory signaling and immune cell activation. Although it remains unknown which cell surface markers signify a proinflammatory phenotype, increased isolectin binding occurs on CD11b-expressing immune cells within injured brain tissue. Several reports have confirmed the efficacy of human umbilical cord blood (HUCB) cell therapy in reducing ischemic injury in rat after middle cerebral artery occlusion (MCAO), and these effects were attributed in part to dampened neuroinflammation. The present study examined the time course of lectin binding to cells of microglia/macrophage lineage within 96 hr after MCAO and whether delayed HUCB cell treatment alters the migration and/or morphological characteristics of these cells throughout the period of infarct expansion. Isolectin binding was up-regulated in response to injury, was maximal at 96 hr, and colocalized with cells that expressed the putative proinflammatory markers MMP-9 and nitric oxide. Isolectin-tagged fluorescence was also significantly increased at 72 hr and localized to greater numbers of amoeboid, CD11b-expressing cells relative to 51 hr. Treatment with 1 x 10(6) HUCB cells significantly reduced total lectin binding at 72 hr, as well as the total area occupied by lectin-tagged fluorescence at both 51 and 72 hr, relative to vehicle-treated controls. This effect was accompanied by a shift in the morphology of CD11b-positive cells from amoeboid to ramified shape. These data indicate that HUCB cell therapy suppressed the recruitment of proinflammatory, isolectin-binding cells during the period of infarct expansion, thus offering a potential mechanism for the protective effects of HUCB cell therapy.
authors.affiliation: Department of Molecular Pharmacology and Physiology, College of Medicine, University of South Florida, Tampa, Florida 33612, USA.
authors.forename: Christopher C
authors.initials: CC
authors.lastname: Leonardo
authors.forename: Aaron A
authors.initials: AA
authors.lastname: Hall
authors.forename: Lisa A
authors.initials: LA
authors.lastname: Collier
authors.forename: Craig T
authors.initials: CT
authors.lastname: Ajmo
authors.forename: Alison E
authors.initials: AE
authors.lastname: Willing
authors.forename: Keith R
authors.initials: KR
authors.lastname: Pennypacker
mesh_terms: D000818:Animals; D039481:CD11b Antigen / Q000378:metabolism; D002465:Cell Movement; D036101:Cord Blood Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D066298:In Vitro Techniques; D020244:Infarction, Middle Cerebral Artery / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D037102:Lectins / Q000378:metabolism; D008264:Macrophages / Q000473:pathology / Q000502:physiology*; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism; D017628:Microglia / Q000473:pathology / Q000502:physiology*; D015213:Neuroimmunomodulation; D009569:Nitric Oxide / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
chemical_list: D039481:CD11b Antigen; D037102:Lectins; D009569:Nitric Oxide; D020780:Matrix Metalloproteinase 9